Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants ; day:17 ; month:7 ; year:2017 ; pages:1-9
PharmacoEconomics - open ; (17.7.2017), 1-9
- Schlagwort
-
Pädiatrie
Kinderkrankheit
- Urheber
-
Shahabi, Ahva
- Beteiligte Personen und Organisationen
-
Peneva, Desi
Incerti, Devin
McLaurin, Kimmie
Stevens, Warren
SpringerLink (Online service)
- DOI
-
10.1007/s41669-017-0042-3
- URN
-
urn:nbn:de:1111-201708205376
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shahabi, Ahva
- Peneva, Desi
- Incerti, Devin
- McLaurin, Kimmie
- Stevens, Warren
- SpringerLink (Online service)
Ähnliche Objekte (12)
Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
Respiratory Morbidity in Late-Preterm Infants: Prevention Is Better Than Cure!
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
Short-term respiratory outcomes in late preterm infants
New Developments in Respiratory Support for Preterm Infants
Hemodynamic consequences of respiratory interventions in preterm infants
Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
Respiratory Morbidity in Late-Preterm Infants: Prevention Is Better Than Cure!
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
Short-term respiratory outcomes in late preterm infants
New Developments in Respiratory Support for Preterm Infants
Hemodynamic consequences of respiratory interventions in preterm infants
Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
Respiratory Morbidity in Late-Preterm Infants: Prevention Is Better Than Cure!
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
Short-term respiratory outcomes in late preterm infants
New Developments in Respiratory Support for Preterm Infants